How we helped our client maximise uptake and fine-tune the marketing strategy for their vaccine product in China
Our client’s vaccine to protect against a condition prevalent in older adults had recently launched and secondary research was required to enable them to understand more about their target healthcare consumer and attitudes to health, well-being and vaccination. They needed to build a complete picture of how consumers are influenced, such as whether they are more influenced by HCP advice or online forums and social media. Furthermore they needed to develop an understanding for other out-of-pocket (OOP) competitor vaccines and what the future healthcare initiatives mean for vaccination in general.
How we helped our client identify where to play and how to win for their hospital product in India
Our client has a hospital care portfolio which is marketed globally. Despite a low per capita use of the product in India, the annual growth rate of usage is among the highest in the world. It was therefore critical for our client to understand which channels they should focus on (where to play) and what points of differentiation would enable them to gain market share in those chosen channels (how to win).
How we uncovered unmet needs using social media listening
Our client wanted to further their understanding of the impacts a long-term rare skin condition can have on patients by exploring the patient journey. Market research was required to identify opportunities for improving the patient experience and inform the brand strategy for their product.
How we helped our client understand current and future combination pricing strategies in the Multiple Myeloma market
Our client had their product for multiple myeloma (MM) approved in several lines of therapy combined with different backbones. Their product was also being studied in some other indications with additional backbones and was anticipated to receive approval in the coming years. With several other competitive therapies available on the market, including many branded combination products, our client anticipated that payers might start considering strategies to manage combination therapies in the future. Therefore, they wanted to understand what the current and future combination pricing strategies were for oncology products, with a focus on MM and their product.
How we helped assess the asthma market landscape in emerging markets
Our client was jointly developing a fully-human monoclonal antibody (mAB) with a number of potential immunological indications. In order to prepare for launch, primary and secondary market research was required to understand more fully the asthma landscape.